#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-11	Association	_
1-2	12-14	of	_
1-3	15-42	Magnetoencephalographically	_
1-4	43-51	Measured	_
1-5	52-66	High-Frequency	_
1-6	67-79	Oscillations	_
1-7	80-82	in	_
1-8	83-89	Visual	_
1-9	90-96	Cortex	_
1-10	97-101	With	_
1-11	102-109	Circuit	_
1-12	110-122	Dysfunctions	_
1-13	123-125	in	_
1-14	126-131	Local	_
1-15	132-135	and	_
1-16	136-147	Large-scale	_
1-17	148-156	Networks	_
1-18	157-163	During	_
1-19	164-172	Emerging	_
1-20	173-182	Psychosis	_
1-21	183-186	Key	_
1-22	187-193	Points	_
1-23	194-202	Question	_
1-24	203-206	Are	_
1-25	207-221	high-frequency	_
1-26	222-234	oscillations	_
1-27	235-237	in	_
1-28	238-244	visual	_
1-29	245-251	cortex	_
1-30	252-260	impaired	_
1-31	261-267	during	_
1-32	268-273	early	_
1-33	274-280	stages	_
1-34	281-283	of	_
1-35	284-293	psychosis	_
1-36	294-295	?	_

2-1	296-304	Findings	_
2-2	305-307	In	_
2-3	308-312	this	_
2-4	313-328	cross-sectional	_
2-5	329-334	study	_
2-6	335-336	,	_
2-7	337-342	there	_
2-8	343-347	were	_
2-9	348-359	significant	_
2-10	360-371	impairments	_
2-11	372-374	in	_
2-12	375-378	the	_
2-13	379-390	variability	_
2-14	391-392	,	_
2-15	393-398	power	_
2-16	399-400	,	_
2-17	401-404	and	_
2-18	405-417	connectivity	_
2-19	418-420	of	_
2-20	421-427	neural	_
2-21	428-440	oscillations	_
2-22	441-447	during	_
2-23	448-454	visual	_
2-24	455-465	processing	_
2-25	466-468	in	_
2-26	469-477	clinical	_
2-27	478-487	high-risk	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
2-28	488-500	participants	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
2-29	501-504	and	_
2-30	505-513	patients	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
2-31	514-518	with	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
2-32	519-532	first-episode	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
2-33	533-542	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
2-34	543-547	that	_
2-35	548-552	were	_
2-36	553-563	associated	_
2-37	564-568	with	_
2-38	569-577	impaired	_
2-39	578-589	functioning	_
2-40	590-593	and	_
2-41	594-603	cognitive	_
2-42	604-612	deficits	_
2-43	613-614	.	_

3-1	615-623	Moreover	_
3-2	624-625	,	_
3-3	626-629	the	_
3-4	630-639	increased	_
3-5	640-651	variability	_
3-6	652-654	of	_
3-7	655-661	γ-band	_
3-8	662-674	oscillations	_
3-9	675-677	in	_
3-10	678-684	visual	_
3-11	685-691	cortex	_
3-12	692-695	was	_
3-13	696-700	also	_
3-14	701-711	associated	_
3-15	712-716	with	_
3-16	717-720	the	_
3-17	721-732	persistence	_
3-18	733-735	of	_
3-19	736-748	subthreshold	_
3-20	749-758	psychotic	_
3-21	759-767	symptoms	_
3-22	768-770	in	_
3-23	771-779	clinical	_
3-24	780-789	high-risk	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
3-25	790-802	participants	_
3-26	803-804	.	_

4-1	805-812	Meaning	_
4-2	813-821	Impaired	_
4-3	822-836	high-frequency	_
4-4	837-849	oscillations	_
4-5	850-852	in	_
4-6	853-859	visual	_
4-7	860-866	cortex	_
4-8	867-870	are	_
4-9	871-873	an	_
4-10	874-883	important	_
4-11	884-890	aspect	_
4-12	891-893	of	_
4-13	894-901	circuit	_
4-14	902-913	dysfunction	_
4-15	914-915	,	_
4-16	916-921	which	_
4-17	922-927	could	_
4-18	928-938	constitute	_
4-19	939-940	a	_
4-20	941-950	biomarker	_
4-21	951-954	for	_
4-22	955-963	clinical	_
4-23	964-971	staging	_
4-24	972-974	of	_
4-25	975-983	emerging	_
4-26	984-993	psychosis	_
4-27	994-995	.	_

5-1	996-1006	Importance	_
5-2	1007-1016	Psychotic	_
5-3	1017-1026	disorders	_
5-4	1027-1030	are	_
5-5	1031-1044	characterized	_
5-6	1045-1047	by	_
5-7	1048-1059	impairments	_
5-8	1060-1062	in	_
5-9	1063-1069	neural	_
5-10	1070-1082	oscillations	_
5-11	1083-1084	,	_
5-12	1085-1088	but	_
5-13	1089-1092	the	_
5-14	1093-1099	nature	_
5-15	1100-1102	of	_
5-16	1103-1106	the	_
5-17	1107-1114	deficit	_
5-18	1115-1116	,	_
5-19	1117-1120	the	_
5-20	1121-1131	trajectory	_
5-21	1132-1138	across	_
5-22	1139-1146	illness	_
5-23	1147-1153	stages	_
5-24	1154-1155	,	_
5-25	1156-1159	and	_
5-26	1160-1170	functional	_
5-27	1171-1180	relevance	_
5-28	1181-1187	remain	_
5-29	1188-1195	unclear	_
5-30	1196-1197	.	_

6-1	1198-1208	Objectives	_
6-2	1209-1211	To	_
6-3	1212-1219	examine	_
6-4	1220-1227	whether	_
6-5	1228-1235	changes	_
6-6	1236-1238	in	_
6-7	1239-1247	spectral	_
6-8	1248-1253	power	_
6-9	1254-1255	,	_
6-10	1256-1261	phase	_
6-11	1262-1269	locking	_
6-12	1270-1271	,	_
6-13	1272-1275	and	_
6-14	1276-1286	functional	_
6-15	1287-1299	connectivity	_
6-16	1300-1302	in	_
6-17	1303-1309	visual	_
6-18	1310-1316	cortex	_
6-19	1317-1320	are	_
6-20	1321-1328	present	_
6-21	1329-1335	during	_
6-22	1336-1344	emerging	_
6-23	1345-1354	psychosis	_
6-24	1355-1358	and	_
6-25	1359-1366	whether	_
6-26	1367-1372	these	_
6-27	1373-1386	abnormalities	_
6-28	1387-1390	are	_
6-29	1391-1401	associated	_
6-30	1402-1406	with	_
6-31	1407-1415	clinical	_
6-32	1416-1424	outcomes	_
6-33	1425-1426	.	_

7-1	1427-1433	Design	_
7-2	1434-1435	,	_
7-3	1436-1443	Setting	_
7-4	1444-1445	,	_
7-5	1446-1449	and	_
7-6	1450-1462	Participants	_
7-7	1463-1465	In	_
7-8	1466-1470	this	_
7-9	1471-1486	cross-sectional	_
7-10	1487-1492	study	_
7-11	1493-1494	,	_
7-12	1495-1507	participants	_
7-13	1508-1515	meeting	_
7-14	1516-1524	clinical	_
7-15	1525-1534	high-risk	_
7-16	1535-1543	criteria	_
7-17	1544-1547	for	_
7-18	1548-1557	psychosis	_
7-19	1558-1559	,	_
7-20	1560-1572	participants	_
7-21	1573-1577	with	http://maven.renci.org/NeuroBridge/neurobridge#SubjectwithoutDisorder
7-22	1578-1591	first-episode	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
7-23	1592-1601	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
7-24	1602-1603	,	_
7-25	1604-1616	participants	_
7-26	1617-1621	with	_
7-27	1622-1631	affective	_
7-28	1632-1641	disorders	http://maven.renci.org/NeuroBridge/neurobridge#ExtrapyramidalDisease
7-29	1642-1645	and	_
7-30	1646-1655	substance	_
7-31	1656-1661	abuse	_
7-32	1662-1663	,	_
7-33	1664-1667	and	_
7-34	1668-1669	a	_
7-35	1670-1675	group	_
7-36	1676-1678	of	_
7-37	1679-1686	control	_
7-38	1687-1699	participants	_
7-39	1700-1704	were	_
7-40	1705-1714	recruited	_
7-41	1715-1716	.	_

8-1	1717-1729	Participants	_
8-2	1730-1739	underwent	_
8-3	1740-1752	measurements	_
8-4	1753-1757	with	_
8-5	1758-1780	magnetoencephalography	_
8-6	1781-1784	and	_
8-7	1785-1793	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
8-8	1794-1803	resonance	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
8-9	1804-1811	imaging	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
8-10	1812-1813	.	_

9-1	1814-1818	Data	_
9-2	1819-1827	analysis	_
9-3	1828-1831	was	_
9-4	1832-1839	carried	_
9-5	1840-1843	out	_
9-6	1844-1851	between	_
9-7	1852-1856	2018	_
9-8	1857-1860	and	_
9-9	1861-1865	2019	_
9-10	1866-1867	.	_

10-1	1868-1872	Main	_
10-2	1873-1881	Outcomes	_
10-3	1882-1885	and	_
10-4	1886-1894	Measures	_
10-5	1895-1920	Magnetoencephalographical	_
10-6	1921-1929	activity	_
10-7	1930-1933	was	_
10-8	1934-1942	examined	_
10-9	1943-1945	in	_
10-10	1946-1949	the	_
10-11	1950-1952	1-	_
10-12	1953-1955	to	_
10-13	1956-1961	90-Hz	_
10-14	1962-1971	frequency	_
10-15	1972-1977	range	_
10-16	1978-1980	in	_
10-17	1981-1992	combination	_
10-18	1993-1997	with	_
10-19	1998-2004	source	_
10-20	2005-2019	reconstruction	_
10-21	2020-2026	during	_
10-22	2027-2028	a	_
10-23	2029-2035	visual	_
10-24	2036-2043	grating	_
10-25	2044-2048	task	_
10-26	2049-2050	.	_

11-1	2051-2064	Event-related	_
11-2	2065-2071	fields	_
11-3	2072-2073	,	_
11-4	2074-2079	power	_
11-5	2080-2090	modulation	_
11-6	2091-2092	,	_
11-7	2093-2103	intertrial	_
11-8	2104-2109	phase	_
11-9	2110-2121	consistency	_
11-10	2122-2123	,	_
11-11	2124-2127	and	_
11-12	2128-2140	connectivity	_
11-13	2141-2149	measures	_
11-14	2150-2152	in	_
11-15	2153-2159	visual	_
11-16	2160-2163	and	_
11-17	2164-2171	frontal	_
11-18	2172-2180	cortices	_
11-19	2181-2185	were	_
11-20	2186-2196	associated	_
11-21	2197-2201	with	_
11-22	2202-2220	neuropsychological	_
11-23	2221-2227	scores	_
11-24	2228-2229	,	_
11-25	2230-2242	psychosocial	_
11-26	2243-2254	functioning	_
11-27	2255-2256	,	_
11-28	2257-2260	and	_
11-29	2261-2269	clinical	_
11-30	2270-2278	symptoms	_
11-31	2279-2281	as	_
11-32	2282-2286	well	_
11-33	2287-2289	as	_
11-34	2290-2301	persistence	_
11-35	2302-2304	of	_
11-36	2305-2317	subthreshold	_
11-37	2318-2327	psychotic	_
11-38	2328-2336	symptoms	_
11-39	2337-2339	at	_
11-40	2340-2342	12	_
11-41	2343-2349	months	_
11-42	2350-2351	.	_

12-1	2352-2359	Results	_
12-2	2360-2363	The	_
12-3	2364-2369	study	_
12-4	2370-2382	participants	_
12-5	2383-2391	included	_
12-6	2392-2397	those	_
12-7	2398-2405	meeting	_
12-8	2406-2414	clinical	_
12-9	2415-2424	high-risk	_
12-10	2425-2433	criteria	_
12-11	2434-2437	for	_
12-12	2438-2447	psychosis	_
12-13	2448-2449	(	_
12-14	2450-2451	n	_
12-15	2452-2453	=	_
12-16	2454-2457	119	_
12-17	2458-2459	;	_
12-18	2460-2464	mean	_
12-19	2465-2466	[	_
12-20	2467-2469	SD	_
12-21	2470-2471	]	_
12-22	2472-2475	age	_
12-23	2476-2477	,	_
12-24	2478-2480	22	_
12-25	2481-2482	[	_
12-26	2483-2486	4.4	_
12-27	2487-2488	]	_
12-28	2489-2494	years	_
12-29	2495-2496	;	_
12-30	2497-2499	32	_
12-31	2500-2503	men	_
12-32	2504-2505	)	_
12-33	2506-2507	,	_
12-34	2508-2510	26	_
12-35	2511-2519	patients	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
12-36	2520-2524	with	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
12-37	2525-2538	first-episode	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
12-38	2539-2548	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
12-39	2549-2550	(	_
12-40	2551-2555	mean	_
12-41	2556-2557	[	_
12-42	2558-2560	SD	_
12-43	2561-2562	]	_
12-44	2563-2566	age	_
12-45	2567-2568	,	_
12-46	2569-2571	24	_
12-47	2572-2573	[	_
12-48	2574-2577	4.2	_
12-49	2578-2579	]	_
12-50	2580-2585	years	_
12-51	2586-2587	;	_
12-52	2588-2590	16	_
12-53	2591-2594	men	_
12-54	2595-2596	)	_
12-55	2597-2598	,	_
12-56	2599-2601	38	_
12-57	2602-2614	participants	http://maven.renci.org/NeuroBridge/neurobridge#PsychoactiveSubstanceAbuse
12-58	2615-2619	with	http://maven.renci.org/NeuroBridge/neurobridge#PsychoactiveSubstanceAbuse
12-59	2620-2629	affective	http://maven.renci.org/NeuroBridge/neurobridge#PsychoactiveSubstanceAbuse
12-60	2630-2639	disorders	http://maven.renci.org/NeuroBridge/neurobridge#PsychoactiveSubstanceAbuse
12-61	2640-2643	and	http://maven.renci.org/NeuroBridge/neurobridge#PsychoactiveSubstanceAbuse
12-62	2644-2653	substance	http://maven.renci.org/NeuroBridge/neurobridge#PsychoactiveSubstanceAbuse
12-63	2654-2659	abuse	http://maven.renci.org/NeuroBridge/neurobridge#PsychoactiveSubstanceAbuse
12-64	2660-2661	(	_
12-65	2662-2666	mean	_
12-66	2667-2668	[	_
12-67	2669-2671	SD	_
12-68	2672-2673	]	_
12-69	2674-2677	age	_
12-70	2678-2679	,	_
12-71	2680-2682	23	_
12-72	2683-2684	[	_
12-73	2685-2688	4.7	_
12-74	2689-2690	]	_
12-75	2691-2696	years	_
12-76	2697-2698	;	_
12-77	2699-2701	11	_
12-78	2702-2705	men	_
12-79	2706-2707	)	_
12-80	2708-2709	,	_
12-81	2710-2713	and	_
12-82	2714-2716	49	_
12-83	2717-2724	control	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
12-84	2725-2737	participants	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
12-85	2738-2739	(	_
12-86	2740-2744	mean	_
12-87	2745-2748	age	_
12-88	2749-2750	[	_
12-89	2751-2753	SD	_
12-90	2754-2755	]	_
12-91	2756-2757	,	_
12-92	2758-2760	23	_
12-93	2761-2762	[	_
12-94	2763-2766	3.6	_
12-95	2767-2768	]	_
12-96	2769-2774	years	_
12-97	2775-2776	;	_
12-98	2777-2779	16	_
12-99	2780-2783	men	_
12-100	2784-2785	)	_
12-101	2786-2787	.	_

13-1	2788-2796	Clinical	_
13-2	2797-2806	high-risk	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
13-3	2807-2819	participants	_
13-4	2820-2823	and	_
13-5	2824-2832	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
13-6	2833-2837	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
13-7	2838-2851	first-episode	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
13-8	2852-2861	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
13-9	2862-2866	were	_
13-10	2867-2880	characterized	_
13-11	2881-2883	by	_
13-12	2884-2891	reduced	_
13-13	2892-2897	phase	_
13-14	2898-2909	consistency	_
13-15	2910-2912	of	_
13-16	2913-2921	β/γ-band	_
13-17	2922-2934	oscillations	_
13-18	2935-2937	in	_
13-19	2938-2944	visual	_
13-20	2945-2951	cortex	_
13-21	2952-2953	(	_
13-22	2954-2955	d	_
13-23	2956-2957	=	_
13-24	2958-2964	0.63/d	_
13-25	2965-2966	=	_
13-26	2967-2971	0.93	_
13-27	2972-2973	)	_
13-28	2974-2975	.	_

14-1	2976-2984	Moreover	_
14-2	2985-2986	,	_
14-3	2987-2990	the	_
14-4	2991-3004	first-episode	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
14-5	3005-3014	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
14-6	3015-3020	group	_
14-7	3021-3024	was	_
14-8	3025-3029	also	_
14-9	3030-3043	characterized	_
14-10	3044-3046	by	_
14-11	3047-3054	reduced	_
14-12	3055-3064	occipital	_
14-13	3065-3071	γ-band	_
14-14	3072-3077	power	_
14-15	3078-3079	(	_
14-16	3080-3081	d	_
14-17	3082-3083	=	_
14-18	3084-3088	1.14	_
14-19	3089-3090	)	_
14-20	3091-3094	and	_
14-21	3095-3102	altered	_
14-22	3103-3109	visual	_
14-23	3110-3116	cortex	_
14-24	3117-3129	connectivity	_
14-25	3130-3131	(	_
14-26	3132-3133	d	_
14-27	3134-3135	=	_
14-28	3136-3145	0.74-0.84	_
14-29	3146-3147	)	_
14-30	3148-3149	.	_

15-1	3150-3158	Impaired	_
15-2	3159-3175	fronto-occipital	_
15-3	3176-3188	connectivity	_
15-4	3189-3192	was	_
15-5	3193-3200	present	_
15-6	3201-3203	in	_
15-7	3204-3208	both	_
15-8	3209-3217	clinical	_
15-9	3218-3227	high-risk	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
15-10	3228-3240	participants	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
15-11	3241-3242	(	_
15-12	3243-3244	d	_
15-13	3245-3246	=	_
15-14	3247-3251	0.54	_
15-15	3252-3253	)	_
15-16	3254-3257	and	_
15-17	3258-3266	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
15-18	3267-3271	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
15-19	3272-3285	first-episode	_
15-20	3286-3295	psychosis	_
15-21	3296-3297	(	_
15-22	3298-3299	d	_
15-23	3300-3301	=	_
15-24	3302-3306	0.84	_
15-25	3307-3308	)	_
15-26	3309-3310	.	_

16-1	3311-3322	Importantly	_
16-2	3323-3324	,	_
16-3	3325-3335	reductions	_
16-4	3336-3338	in	_
16-5	3339-3349	intertrial	_
16-6	3350-3355	phase	_
16-7	3356-3365	coherence	_
16-8	3366-3375	predicted	_
16-9	3376-3387	persistence	_
16-10	3388-3390	of	_
16-11	3391-3403	subthreshold	_
16-12	3404-3413	psychosis	_
16-13	3414-3416	in	_
16-14	3417-3425	clinical	_
16-15	3426-3435	high-risk	_
16-16	3436-3448	participants	_
16-17	3449-3450	(	_
16-18	3451-3459	receiver	_
16-19	3460-3469	operating	_
16-20	3470-3484	characteristic	_
16-21	3485-3489	area	_
16-22	3490-3495	under	_
16-23	3496-3501	curve	_
16-24	3502-3503	=	_
16-25	3504-3509	0.728	_
16-26	3510-3511	;	_
16-27	3512-3514	95	_
16-28	3515-3516	%	_
16-29	3517-3519	CI	_
16-30	3520-3521	,	_
16-31	3522-3533	0.612-0.841	_
16-32	3534-3535	;	_
16-33	3536-3537	P	_
16-34	3538-3539	=	_
16-35	3540-3544	.001	_
16-36	3545-3546	)	_
16-37	3547-3548	.	_

17-1	3549-3560	Conclusions	_
17-2	3561-3564	and	_
17-3	3565-3574	Relevance	_
17-4	3575-3589	High-frequency	_
17-5	3590-3602	oscillations	_
17-6	3603-3606	are	_
17-7	3607-3615	impaired	_
17-8	3616-3618	in	_
17-9	3619-3622	the	_
17-10	3623-3629	visual	_
17-11	3630-3636	cortex	_
17-12	3637-3643	during	_
17-13	3644-3652	emerging	_
17-14	3653-3662	psychosis	_
17-15	3663-3666	and	_
17-16	3667-3670	may	_
17-17	3671-3673	be	_
17-18	3674-3680	linked	_
17-19	3681-3683	to	_
17-20	3684-3694	behavioral	_
17-21	3695-3698	and	_
17-22	3699-3707	clinical	_
17-23	3708-3719	impairments	_
17-24	3720-3721	.	_

18-1	3722-3730	Impaired	_
18-2	3731-3736	phase	_
18-3	3737-3748	consistency	_
18-4	3749-3751	of	_
18-5	3752-3758	γ-band	_
18-6	3759-3771	oscillations	_
18-7	3772-3775	was	_
18-8	3776-3780	also	_
18-9	3781-3791	associated	_
18-10	3792-3796	with	_
18-11	3797-3800	the	_
18-12	3801-3812	persistence	_
18-13	3813-3815	of	_
18-14	3816-3828	subthreshold	_
18-15	3829-3838	psychosis	_
18-16	3839-3840	,	_
18-17	3841-3851	suggesting	_
18-18	3852-3856	that	_
18-19	3857-3882	magnetoencephalographical	_
18-20	3883-3891	measured	_
18-21	3892-3898	neural	_
18-22	3899-3911	oscillations	_
18-23	3912-3917	could	_
18-24	3918-3928	constitute	_
18-25	3929-3930	a	_
18-26	3931-3940	biomarker	_
18-27	3941-3944	for	_
18-28	3945-3953	clinical	_
18-29	3954-3961	staging	_
18-30	3962-3964	of	_
18-31	3965-3973	emerging	_
18-32	3974-3983	psychosis	_
18-33	3984-3985	.	_

19-1	3986-3990	This	_
19-2	3991-3996	study	_
19-3	3997-4005	examines	_
19-4	4006-4013	whether	_
19-5	4014-4021	changes	_
19-6	4022-4024	in	_
19-7	4025-4033	spectral	_
19-8	4034-4039	power	_
19-9	4040-4041	,	_
19-10	4042-4047	phase	_
19-11	4048-4055	locking	_
19-12	4056-4057	,	_
19-13	4058-4061	and	_
19-14	4062-4072	functional	_
19-15	4073-4085	connectivity	_
19-16	4086-4088	in	_
19-17	4089-4095	visual	_
19-18	4096-4102	cortex	_
19-19	4103-4106	are	_
19-20	4107-4114	present	_
19-21	4115-4121	during	_
19-22	4122-4130	emerging	_
19-23	4131-4140	psychosis	_
19-24	4141-4144	and	_
19-25	4145-4152	whether	_
19-26	4153-4158	these	_
19-27	4159-4172	abnormalities	_
19-28	4173-4176	are	_
19-29	4177-4187	associated	_
19-30	4188-4192	with	_
19-31	4193-4201	clinical	_
19-32	4202-4210	outcomes	_
19-33	4211-4212	.	_

20-1	4213-4220	Methods	http://maven.renci.org/NeuroBridge/neurobridge#DataCollectionMethod
20-2	4221-4233	Participants	_
20-3	4234-4238	Four	_
20-4	4239-4245	groups	_
20-5	4246-4248	of	_
20-6	4249-4261	participants	_
20-7	4262-4263	(	_
20-8	4264-4269	total	_
20-9	4270-4271	n	_
20-10	4272-4273	=	_
20-11	4274-4277	232	_
20-12	4278-4279	)	_
20-13	4280-4284	were	_
20-14	4285-4294	recruited	_
20-15	4295-4296	:	_
20-16	4297-4298	(	_
20-17	4299-4300	1	_
20-18	4301-4302	)	_
20-19	4303-4315	participants	_
20-20	4316-4323	meeting	_
20-21	4324-4329	CHR-P	_
20-22	4330-4338	criteria	_
20-23	4339-4340	(	_
20-24	4341-4342	n	_
20-25	4343-4344	=	_
20-26	4345-4348	119	_
20-27	4349-4350	)	_
20-28	4351-4355	from	_
20-29	4356-4359	the	_
20-30	4360-4367	ongoing	_
20-31	4368-4373	Youth	_
20-32	4374-4380	Mental	http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthQuestionnaire
20-33	4381-4387	Health	http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthQuestionnaire
20-34	4388-4392	Risk	http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthQuestionnaire
20-35	4393-4396	and	http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthQuestionnaire
20-36	4397-4407	Resilience	http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthQuestionnaire
20-37	4408-4409	(	http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthQuestionnaire
20-38	4410-4414	YouR	http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthQuestionnaire
20-39	4415-4416	)	http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthQuestionnaire
20-40	4417-4422	Study	_
20-41	4423-4424	;	_
20-42	4425-4426	(	_
20-43	4427-4428	2	_
20-44	4429-4430	)	_
20-45	4431-4433	38	_
20-46	4434-4446	participants	_
20-47	4447-4450	who	_
20-48	4451-4454	did	_
20-49	4455-4458	not	_
20-50	4459-4463	meet	_
20-51	4464-4469	CHR-P	_
20-52	4470-4478	criteria	_
20-53	4479-4480	(	_
20-54	4481-4486	CHR-N	_
20-55	4487-4488	)	_
20-56	4489-4492	and	_
20-57	4493-4497	were	_
20-58	4498-4511	characterized	_
20-59	4512-4514	by	_
20-60	4515-4527	nonpsychotic	_
20-61	4528-4537	disorders	_
20-62	4538-4539	,	_
20-63	4540-4544	such	_
20-64	4545-4547	as	_
20-65	4548-4557	affective	_
20-66	4558-4567	disorders	_
20-67	4568-4569	(	_
20-68	4570-4571	n	_
20-69	4572-4573	=	_
20-70	4574-4576	11	_
20-71	4577-4578	)	_
20-72	4579-4580	,	_
20-73	4581-4588	anxiety	_
20-74	4589-4598	disorders	_
20-75	4599-4600	(	_
20-76	4601-4602	n	_
20-77	4603-4604	=	_
20-78	4605-4607	16	_
20-79	4608-4609	)	_
20-80	4610-4611	,	_
20-81	4612-4618	eating	_
20-82	4619-4628	disorders	_
20-83	4629-4630	(	_
20-84	4631-4632	n	_
20-85	4633-4634	=	_
20-86	4635-4636	1	_
20-87	4637-4638	)	_
20-88	4639-4640	,	_
20-89	4641-4647	and/or	_
20-90	4648-4657	substance	_
20-91	4658-4663	abuse	_
20-92	4664-4665	(	_
20-93	4666-4667	n	_
20-94	4668-4669	=	_
20-95	4670-4672	10	_
20-96	4673-4674	)	_
20-97	4675-4676	;	_
20-98	4677-4678	(	_
20-99	4679-4680	3	_
20-100	4681-4682	)	_
20-101	4683-4685	26	_
20-102	4686-4694	patients	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
20-103	4695-4699	with	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
20-104	4700-4703	FEP	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
20-105	4704-4705	(	_
20-106	4706-4708	13	_
20-107	4709-4728	antipsychotic-naive	_
20-108	4729-4730	)	_
20-109	4731-4732	;	_
20-110	4733-4736	and	_
20-111	4737-4738	(	_
20-112	4739-4740	4	_
20-113	4741-4742	)	_
20-114	4743-4745	49	_
20-115	4746-4753	healthy	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
20-116	4754-4761	control	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
20-117	4762-4773	individuals	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
20-118	4774-4775	(	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
20-119	4776-4778	HC	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
20-120	4779-4780	)	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
20-121	4781-4788	without	_
20-122	4789-4791	an	_
20-123	4792-4796	axis	_
20-124	4797-4798	I	_
20-125	4799-4808	diagnosis	_
20-126	4809-4811	or	_
20-127	4812-4818	family	_
20-128	4819-4826	history	_
20-129	4827-4829	of	_
20-130	4830-4839	psychotic	_
20-131	4840-4849	disorders	_
20-132	4850-4851	.	_

21-1	4852-4856	Data	_
21-2	4857-4861	from	_
21-3	4862-4864	10	_
21-4	4865-4873	patients	_
21-5	4874-4878	with	_
21-6	4879-4882	FEP	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
21-7	4883-4886	and	_
21-8	4887-4889	10	_
21-9	4890-4892	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
21-10	4893-4897	have	_
21-11	4898-4902	been	_
21-12	4903-4912	published	_
21-13	4913-4923	previously	_
21-14	4924-4925	.	_

22-1	4926-4929	The	_
22-2	4930-4935	CHR-P	http://maven.renci.org/NeuroBridge/neurobridge#ChronicPain
22-3	4936-4942	status	_
22-4	4943-4946	was	_
22-5	4947-4956	confirmed	_
22-6	4957-4959	by	_
22-7	4960-4974	ultrahigh-risk	_
22-8	4975-4983	criteria	_
22-9	4984-4993	according	_
22-10	4994-4996	to	_
22-11	4997-5000	the	_
22-12	5001-5014	Comprehensive	http://maven.renci.org/NeuroBridge/neurobridge#ComprehensiveAssessmentofSymptomsandHistory
22-13	5015-5025	Assessment	http://maven.renci.org/NeuroBridge/neurobridge#ComprehensiveAssessmentofSymptomsandHistory
22-14	5026-5028	of	http://maven.renci.org/NeuroBridge/neurobridge#ComprehensiveAssessmentofSymptomsandHistory
22-15	5029-5031	At	http://maven.renci.org/NeuroBridge/neurobridge#ComprehensiveAssessmentofSymptomsandHistory
22-16	5032-5036	Risk	http://maven.renci.org/NeuroBridge/neurobridge#ComprehensiveAssessmentofSymptomsandHistory
22-17	5037-5043	Mental	http://maven.renci.org/NeuroBridge/neurobridge#ComprehensiveAssessmentofSymptomsandHistory
22-18	5044-5050	States	http://maven.renci.org/NeuroBridge/neurobridge#ComprehensiveAssessmentofSymptomsandHistory
22-19	5051-5052	(	http://maven.renci.org/NeuroBridge/neurobridge#ComprehensiveAssessmentofSymptomsandHistory
22-20	5053-5059	CAARMS	http://maven.renci.org/NeuroBridge/neurobridge#ComprehensiveAssessmentofSymptomsandHistory
22-21	5060-5061	)	http://maven.renci.org/NeuroBridge/neurobridge#ComprehensiveAssessmentofSymptomsandHistory
22-22	5062-5071	interview	_
22-23	5072-5075	and	_
22-24	5076-5079	the	_
22-25	5080-5089	Cognitive	_
22-26	5090-5102	Disturbances	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
22-27	5103-5106	and	_
22-28	5107-5127	Cognitive-Perceptive	_
22-29	5128-5133	Basic	http://maven.renci.org/NeuroBridge/neurobridge#PosttraumaticStressDisorderSymptomsScale
22-30	5134-5142	Symptoms	http://maven.renci.org/NeuroBridge/neurobridge#PosttraumaticStressDisorderSymptomsScale
22-31	5143-5151	criteria	_
22-32	5152-5161	according	_
22-33	5162-5164	to	_
22-34	5165-5168	the	_
22-35	5169-5182	Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#ChapmanPsychosisProneness
22-36	5183-5192	Proneness	http://maven.renci.org/NeuroBridge/neurobridge#ChapmanPsychosisProneness
22-37	5193-5203	Instrument	http://maven.renci.org/NeuroBridge/neurobridge#ChapmanPsychosisProneness
22-38	5204-5205	,	_
22-39	5206-5211	Adult	_
22-40	5212-5219	version	_
22-41	5220-5221	(	_
22-42	5222-5227	SPI-A	_
22-43	5228-5229	)	_
22-44	5230-5231	(	_
22-45	5232-5235	see	_
22-46	5236-5243	Uhlhaas	_
22-47	5244-5246	et	_
22-48	5247-5249	al	_
22-49	5250-5251	)	_
22-50	5252-5253	.	_

23-1	5254-5262	Patients	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
23-2	5263-5267	with	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
23-3	5268-5271	FEP	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
23-4	5272-5276	were	_
23-5	5277-5285	assessed	_
23-6	5286-5290	with	_
23-7	5291-5294	the	_
23-8	5295-5305	Structured	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
23-9	5306-5314	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
23-10	5315-5324	Interview	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
23-11	5325-5328	for	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
23-12	5329-5335	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
23-13	5336-5337	(	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
23-14	5338-5343	Table	_
23-15	5344-5345	)	_
23-16	5346-5349	and	_
23-17	5350-5354	with	_
23-18	5355-5358	the	_
23-19	5359-5367	Positive	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
23-20	5368-5371	and	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
23-21	5372-5380	Negative	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
23-22	5381-5388	Symptom	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
23-23	5389-5394	Scale	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
23-24	5395-5396	.	_

24-1	5397-5400	For	_
24-2	5401-5404	all	_
24-3	5405-5411	groups	_
24-4	5412-5418	except	_
24-5	5419-5427	patients	_
24-6	5428-5432	with	_
24-7	5433-5436	FEP	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
24-8	5437-5438	,	_
24-9	5439-5453	neurocognition	_
24-10	5454-5457	was	_
24-11	5458-5466	assessed	_
24-12	5467-5471	with	_
24-13	5472-5475	the	_
24-14	5476-5481	Brief	_
24-15	5482-5492	Assessment	http://maven.renci.org/NeuroBridge/neurobridge#BriefAssessmentofCognitioninSchizophrenia
24-16	5493-5495	of	http://maven.renci.org/NeuroBridge/neurobridge#BriefAssessmentofCognitioninSchizophrenia
24-17	5496-5505	Cognition	http://maven.renci.org/NeuroBridge/neurobridge#BriefAssessmentofCognitioninSchizophrenia
24-18	5506-5508	in	http://maven.renci.org/NeuroBridge/neurobridge#BriefAssessmentofCognitioninSchizophrenia
24-19	5509-5522	Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#BriefAssessmentofCognitioninSchizophrenia
24-20	5523-5524	(	http://maven.renci.org/NeuroBridge/neurobridge#BriefAssessmentofCognitioninSchizophrenia
24-21	5525-5529	BACS	http://maven.renci.org/NeuroBridge/neurobridge#BriefAssessmentofCognitioninSchizophrenia
24-22	5530-5531	)	http://maven.renci.org/NeuroBridge/neurobridge#BriefAssessmentofCognitioninSchizophrenia
24-23	5532-5533	.	_

25-1	5534-5537	The	_
25-2	5538-5543	study	_
25-3	5544-5547	was	_
25-4	5548-5556	approved	_
25-5	5557-5559	by	_
25-6	5560-5563	the	_
25-7	5564-5571	ethical	_
25-8	5572-5582	committees	_
25-9	5583-5585	of	_
25-10	5586-5596	University	_
25-11	5597-5599	of	_
25-12	5600-5607	Glasgow	_
25-13	5608-5611	and	_
25-14	5612-5615	the	_
25-15	5616-5624	National	_
25-16	5625-5631	Health	_
25-17	5632-5640	Services	_
25-18	5641-5649	Research	_
25-19	5650-5657	Ethical	_
25-20	5658-5667	Committee	_
25-21	5668-5675	Glasgow	_
25-22	5676-5679	and	_
25-23	5680-5687	Greater	_
25-24	5688-5693	Clyde	_
25-25	5694-5695	.	_

26-1	5696-5699	All	_
26-2	5700-5712	participants	_
26-3	5713-5721	provided	_
26-4	5722-5729	written	_
26-5	5730-5738	informed	_
26-6	5739-5746	consent	_
26-7	5747-5748	.	_

27-1	5749-5757	Clinical	_
27-2	5758-5767	Follow-up	_
27-3	5768-5780	Participants	_
27-4	5781-5788	meeting	_
27-5	5789-5794	CHR-P	_
27-6	5795-5798	and	_
27-7	5799-5804	CHR-N	_
27-8	5805-5813	criteria	_
27-9	5814-5818	were	_
27-10	5819-5829	reassessed	_
27-11	5830-5832	at	_
27-12	5833-5835	3-	_
27-13	5836-5837	,	_
27-14	5838-5840	6-	_
27-15	5841-5842	,	_
27-16	5843-5845	9-	_
27-17	5846-5847	,	_
27-18	5848-5851	12-	_
27-19	5852-5853	,	_
27-20	5854-5857	18-	_
27-21	5858-5859	,	_
27-22	5860-5863	24-	_
27-23	5864-5865	,	_
27-24	5866-5869	30-	_
27-25	5870-5871	,	_
27-26	5872-5875	and	_
27-27	5876-5884	36-month	_
27-28	5885-5894	intervals	_
27-29	5895-5897	to	_
27-30	5898-5905	examine	_
27-31	5906-5917	persistence	_
27-32	5918-5920	of	_
27-33	5921-5926	CHR-P	_
27-34	5927-5935	criteria	_
27-35	5936-5939	and	_
27-36	5940-5950	transition	_
27-37	5951-5953	to	_
27-38	5954-5963	psychosis	_
27-39	5964-5965	(	_
27-40	5966-5974	eMethods	_
27-41	5975-5977	in	_
27-42	5978-5981	the	_
27-43	5982-5992	Supplement	_
27-44	5993-5994	)	_
27-45	5995-5996	.	_

28-1	5997-6004	Stimuli	_
28-2	6005-6008	and	_
28-3	6009-6013	Task	_
28-4	6014-6026	Participants	_
28-5	6027-6031	were	_
28-6	6032-6041	presented	_
28-7	6042-6046	with	_
28-8	6047-6048	3	_
28-9	6049-6055	blocks	_
28-10	6056-6058	of	_
28-11	6059-6061	80	_
28-12	6062-6068	trials	_
28-13	6069-6070	,	_
28-14	6071-6075	with	_
28-15	6076-6080	each	_
28-16	6081-6086	trial	_
28-17	6087-6097	consisting	_
28-18	6098-6100	of	_
28-19	6101-6102	a	_
28-20	6103-6111	circular	_
28-21	6112-6120	sinewave	_
28-22	6121-6128	grating	_
28-23	6129-6133	that	_
28-24	6134-6144	contracted	_
28-25	6145-6151	toward	_
28-26	6152-6159	central	_
28-27	6160-6168	fixation	_
28-28	6169-6170	.	_

29-1	6171-6174	The	_
29-2	6175-6179	task	_
29-3	6180-6182	of	_
29-4	6183-6186	the	_
29-5	6187-6199	participants	_
29-6	6200-6203	was	_
29-7	6204-6206	to	_
29-8	6207-6213	detect	_
29-9	6214-6217	and	_
29-10	6218-6225	respond	_
29-11	6226-6228	by	_
29-12	6229-6235	button	_
29-13	6236-6241	press	_
29-14	6242-6244	to	_
29-15	6245-6246	a	_
29-16	6247-6255	velocity	_
29-17	6256-6264	increase	_
29-18	6265-6267	of	_
29-19	6268-6271	the	_
29-20	6272-6280	stimulus	_
29-21	6281-6282	,	_
29-22	6283-6291	randomly	_
29-23	6292-6301	occurring	_
29-24	6302-6309	between	_
29-25	6310-6313	750	_
29-26	6314-6317	and	_
29-27	6318-6322	3000	_
29-28	6323-6335	milliseconds	_
29-29	6336-6337	(	_
29-30	6338-6344	Figure	_
29-31	6345-6346	1	_
29-32	6347-6348	)	_
29-33	6349-6350	.	_

30-1	6351-6363	Neuroimaging	_
30-2	6364-6386	Magnetoencephalography	http://maven.renci.org/NeuroBridge/neurobridge#Magnetoencephalography
30-3	6387-6391	data	_
30-4	6392-6396	were	_
30-5	6397-6405	acquired	_
30-6	6406-6411	using	_
30-7	6412-6413	a	_
30-8	6414-6425	248-channel	_
30-9	6426-6432	4D-BTI	_
30-10	6433-6445	magnetometer	_
30-11	6446-6452	system	_
30-12	6453-6454	(	_
30-13	6455-6461	MAGNES	_
30-14	6462-6466	3600	_
30-15	6467-6469	WH	_
30-16	6470-6471	,	_
30-17	6472-6485	4-dimensional	_
30-18	6486-6498	neuroimaging	_
30-19	6499-6500	;	_
30-20	6501-6513	Bio-Medicine	_
30-21	6514-6515	)	_
30-22	6516-6517	,	_
30-23	6518-6526	recorded	_
30-24	6527-6531	with	_
30-25	6532-6542	1017.25-Hz	_
30-26	6543-6551	sampling	_
30-27	6552-6556	rate	_
30-28	6557-6560	and	_
30-29	6561-6567	DC-400	_
30-30	6568-6570	Hz	_
30-31	6571-6577	online	_
30-32	6578-6586	filtered	_
30-33	6587-6588	.	_

31-1	6589-6591	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
31-2	6592-6602	anatomical	_
31-3	6603-6608	scans	_
31-4	6609-6610	(	_
31-5	6611-6624	3-dimensional	_
31-6	6625-6647	magnetization-prepared	_
31-7	6648-6653	rapid	_
31-8	6654-6667	gradient-echo	_
31-9	6668-6677	sequences	_
31-10	6678-6679	)	_
31-11	6680-6684	were	_
31-12	6685-6694	collected	_
31-13	6695-6698	for	_
31-14	6699-6715	patient-specific	_
31-15	6716-6722	source	_
31-16	6723-6735	localization	_
31-17	6736-6738	of	_
31-18	6739-6742	MEG	_
31-19	6743-6751	activity	_
31-20	6752-6753	(	_
31-21	6754-6762	eMethods	_
31-22	6763-6765	in	_
31-23	6766-6769	the	_
31-24	6770-6780	Supplement	_
31-25	6781-6782	)	_
31-26	6783-6784	.	_

32-1	6785-6807	Magnetoencephalography	_
32-2	6808-6812	Data	_
32-3	6813-6821	Analysis	_
32-4	6822-6844	Magnetoencephalography	_
32-5	6845-6849	data	_
32-6	6850-6854	were	_
32-7	6855-6863	analyzed	_
32-8	6864-6868	with	_
32-9	6869-6875	MATLAB	_
32-10	6876-6881	using	_
32-11	6882-6885	the	_
32-12	6886-6897	open-source	_
32-13	6898-6907	Fieldtrip	_
32-14	6908-6915	Toolbox	_
32-15	6916-6917	.	_

33-1	6918-6931	Preprocessing	_
33-2	6932-6940	included	_
33-3	6941-6948	correct	_
33-4	6949-6955	trials	_
33-5	6956-6960	only	_
33-6	6961-6965	with	_
33-7	6966-6980	nonoverlapping	_
33-8	6981-6991	3.8-second	_
33-9	6992-7000	segments	_
33-10	7001-7002	(	_
33-11	7003-7011	1-second	_
33-12	7012-7020	baseline	_
33-13	7021-7022	)	_
33-14	7023-7024	,	_
33-15	7025-7029	time	_
33-16	7030-7036	locked	_
33-17	7037-7039	to	_
33-18	7040-7043	the	_
33-19	7044-7049	onset	_
33-20	7050-7052	of	_
33-21	7053-7056	the	_
33-22	7057-7063	visual	_
33-23	7064-7071	grating	_
33-24	7072-7073	.	_

34-1	7074-7078	Line	_
34-2	7079-7084	noise	_
34-3	7085-7088	was	_
34-4	7089-7099	attenuated	_
34-5	7100-7104	with	_
34-6	7105-7106	a	_
34-7	7107-7115	discrete	_
34-8	7116-7121	50-Hz	_
34-9	7122-7129	Fourier	_
34-10	7130-7139	transform	_
34-11	7140-7146	filter	_
34-12	7147-7148	,	_
34-13	7149-7152	and	_
34-14	7153-7159	faulty	_
34-15	7160-7167	sensors	_
34-16	7168-7172	with	_
34-17	7173-7178	large	_
34-18	7179-7185	signal	_
34-19	7186-7194	variance	_
34-20	7195-7197	or	_
34-21	7198-7202	flat	_
34-22	7203-7210	signals	_
34-23	7211-7215	were	_
34-24	7216-7223	removed	_
34-25	7224-7225	.	_

35-1	7226-7230	Data	_
35-2	7231-7235	were	_
35-3	7236-7244	denoised	_
35-4	7245-7253	relative	_
35-5	7254-7256	to	_
35-6	7257-7260	MEG	_
35-7	7261-7270	reference	_
35-8	7271-7279	channels	_
35-9	7280-7283	and	_
35-10	7284-7295	downsampled	_
35-11	7296-7298	to	_
35-12	7299-7302	300	_
35-13	7303-7305	Hz	_
35-14	7306-7307	.	_

36-1	7308-7321	Artifact-free	_
36-2	7322-7326	data	_
36-3	7327-7331	were	_
36-4	7332-7339	created	_
36-5	7340-7342	by	_
36-6	7343-7351	removing	_
36-7	7352-7358	trials	_
36-8	7359-7363	with	_
36-9	7364-7373	excessive	_
36-10	7374-7383	transient	_
36-11	7384-7390	muscle	_
36-12	7391-7399	activity	_
36-13	7400-7401	,	_
36-14	7402-7406	slow	_
36-15	7407-7412	drift	_
36-16	7413-7414	,	_
36-17	7415-7417	or	_
36-18	7418-7433	superconducting	_
36-19	7434-7441	quantum	_
36-20	7442-7454	interference	_
36-21	7455-7461	device	_
36-22	7462-7467	jumps	_
36-23	7468-7473	using	_
36-24	7474-7480	visual	_
36-25	7481-7491	inspection	_
36-26	7492-7493	,	_
36-27	7494-7497	and	_
36-28	7498-7509	independent	_
36-29	7510-7519	component	_
36-30	7520-7534	analysis–based	_
36-31	7535-7542	removal	_
36-32	7543-7545	of	_
36-33	7546-7549	eye	_
36-34	7550-7555	blink	_
36-35	7556-7557	,	_
36-36	7558-7561	eye	_
36-37	7562-7570	movement	_
36-38	7571-7572	,	_
36-39	7573-7576	and	_
36-40	7577-7597	electrocardiographic	_
36-41	7598-7607	artifacts	_
36-42	7608-7609	.	_

37-1	7610-7614	Data	_
37-2	7615-7619	were	_
37-3	7620-7624	then	_
37-4	7625-7634	submitted	_
37-5	7635-7637	to	_
37-6	7638-7652	time-frequency	_
37-7	7653-7654	(	_
37-8	7655-7658	TFR	_
37-9	7659-7660	)	_
37-10	7661-7669	analyses	_
37-11	7670-7671	(	_
37-12	7672-7676	1-90	_
37-13	7677-7679	Hz	_
37-14	7680-7681	,	_
37-15	7682-7690	stepsize	_
37-16	7691-7693	50	_
37-17	7694-7706	milliseconds	_
37-18	7707-7708	,	_
37-19	7709-7712	450	_
37-20	7713-7725	milliseconds	_
37-21	7726-7740	sliding-window	_
37-22	7741-7753	fast-fourier	_
37-23	7754-7765	transformed	_
37-24	7766-7767	[	_
37-25	7768-7771	FFT	_
37-26	7772-7773	]	_
37-27	7774-7775	;	_
37-28	7776-7783	Hanning	_
37-29	7784-7791	tapered	_
37-30	7792-7793	)	_
37-31	7794-7795	,	_
37-32	7796-7804	computed	_
37-33	7805-7808	for	_
37-34	7809-7827	planar-orientation	_
37-35	7828-7839	transformed	_
37-36	7840-7843	MEG	_
37-37	7844-7848	data	_
37-38	7849-7850	.	_

38-1	7851-7862	Whole-brain	_
38-2	7863-7869	source	_
38-3	7870-7880	estimation	_
38-4	7881-7883	of	_
38-5	7884-7890	γ-band	_
38-6	7891-7896	power	_
38-7	7897-7898	(	_
38-8	7899-7904	57-67	_
38-9	7905-7907	Hz	_
38-10	7908-7909	)	_
38-11	7910-7917	between	_
38-12	7918-7921	250	_
38-13	7922-7925	and	_
38-14	7926-7929	750	_
38-15	7930-7942	milliseconds	_
38-16	7943-7946	was	_
38-17	7947-7955	computed	_
38-18	7956-7961	using	_
38-19	7962-7965	the	_
38-20	7966-7973	Dynamic	_
38-21	7974-7981	Imaging	_
38-22	7982-7984	of	_
38-23	7985-7993	Coherent	_
38-24	7994-8001	Sources	_
38-25	8002-8013	beamforming	_
38-26	8014-8022	approach	_
38-27	8023-8024	(	_
38-28	8025-8033	eMethods	_
38-29	8034-8036	in	_
38-30	8037-8040	the	_
38-31	8041-8051	Supplement	_
38-32	8052-8053	)	_
38-33	8054-8055	.	_

39-1	8056-8062	γ-Band	_
39-2	8063-8069	source	_
39-3	8070-8074	data	_
39-4	8075-8079	were	_
39-5	8080-8093	statistically	_
39-6	8094-8100	tested	_
39-7	8101-8107	across	_
39-8	8108-8114	groups	_
39-9	8115-8117	to	_
39-10	8118-8127	determine	_
39-11	8128-8131	the	_
39-12	8132-8140	location	_
39-13	8141-8143	of	_
39-14	8144-8148	main	_
39-15	8149-8156	effects	_
39-16	8157-8158	(	_
39-17	8159-8165	Figure	_
39-18	8166-8167	2	_
39-19	8168-8169	)	_
39-20	8170-8171	.	_

40-1	8172-8177	These	_
40-2	8178-8182	were	_
40-3	8183-8187	then	_
40-4	8188-8192	used	_
40-5	8193-8195	to	_
40-6	8196-8201	guide	_
40-7	8202-8211	selection	_
40-8	8212-8214	of	_
40-9	8215-8218	the	_
40-10	8219-8223	main	_
40-11	8224-8231	regions	_
40-12	8232-8234	of	_
40-13	8235-8243	interest	_
40-14	8244-8245	(	_
40-15	8246-8250	ROIs	_
40-16	8251-8252	)	_
40-17	8253-8256	for	_
40-18	8257-8261	more	_
40-19	8262-8274	fine-grained	_
40-20	8275-8282	virtual	_
40-21	8283-8290	channel	_
40-22	8291-8299	analyses	_
40-23	8300-8301	(	_
40-24	8302-8308	Figure	_
40-25	8309-8310	2	_
40-26	8311-8314	and	_
40-27	8315-8321	Figure	_
40-28	8322-8324	3C	_
40-29	8325-8326	)	_
40-30	8327-8328	(	_
40-31	8329-8337	eMethods	_
40-32	8338-8340	in	_
40-33	8341-8344	the	_
40-34	8345-8355	Supplement	_
40-35	8356-8357	)	_
40-36	8358-8359	.	_

41-1	8360-8367	Virtual	_
41-2	8368-8375	channel	_
41-3	8376-8380	time	_
41-4	8381-8387	series	_
41-5	8388-8392	were	_
41-6	8393-8397	used	_
41-7	8398-8401	for	_
41-8	8402-8405	the	_
41-9	8406-8414	analysis	_
41-10	8415-8417	of	_
41-11	8418-8431	event-related	_
41-12	8432-8438	fields	_
41-13	8439-8440	(	_
41-14	8441-8444	ERF	_
41-15	8445-8446	)	_
41-16	8447-8448	,	_
41-17	8449-8452	TFR	_
41-18	8453-8454	,	_
41-19	8455-8466	inter-trial	_
41-20	8467-8472	phase	_
41-21	8473-8482	coherence	_
41-22	8483-8484	(	_
41-23	8485-8489	ITPC	_
41-24	8490-8491	)	_
41-25	8492-8493	,	_
41-26	8494-8502	baseline	_
41-27	8503-8506	FFT	_
41-28	8507-8508	,	_
41-29	8509-8512	and	_
41-30	8513-8520	Granger	_
41-31	8521-8530	causality	_
41-32	8531-8532	(	_
41-33	8533-8535	GC	_
41-34	8536-8537	)	_
41-35	8538-8539	.	_

42-1	8540-8557	Granger-causality	_
42-2	8558-8567	estimates	_
42-3	8568-8572	were	_
42-4	8573-8581	computed	_
42-5	8582-8587	using	_
42-6	8588-8589	a	_
42-7	8590-8603	nonparametric	_
42-8	8604-8612	approach	_
42-9	8613-8614	,	_
42-10	8615-8624	including	_
42-11	8625-8633	spectral	_
42-12	8634-8641	density	_
42-13	8642-8650	matrices	_
42-14	8651-8660	estimated	_
42-15	8661-8669	directly	_
42-16	8670-8674	from	_
42-17	8675-8683	FFT-data	_
42-18	8684-8685	(	_
42-19	8686-8693	250-750	_
42-20	8694-8706	milliseconds	_
42-21	8707-8708	;	_
42-22	8709-8715	DC-149	_
42-23	8716-8718	Hz	_
42-24	8719-8720	;	_
42-25	8721-8728	Hanning	_
42-26	8729-8736	tapered	_
42-27	8737-8738	;	_
42-28	8739-8743	5-Hz	_
42-29	8744-8753	frequency	_
42-30	8754-8763	smoothing	_
42-31	8764-8765	;	_
42-32	8766-8770	1-Hz	_
42-33	8771-8781	resolution	_
42-34	8782-8783	;	_
42-35	8784-8788	data	_
42-36	8789-8800	zero-padded	_
42-37	8801-8803	to	_
42-38	8804-8805	4	_
42-39	8806-8813	seconds	_
42-40	8814-8815	)	_
42-41	8816-8817	,	_
42-42	8818-8826	followed	_
42-43	8827-8829	by	_
42-44	8830-8836	matrix	_
42-45	8837-8850	factorization	_
42-46	8851-8854	and	_
42-47	8855-8863	variance	_
42-48	8864-8877	decomposition	_
42-49	8878-8879	.	_

43-1	8880-8886	Epochs	_
43-2	8887-8891	were	_
43-3	8892-8897	split	_
43-4	8898-8902	into	_
43-5	8903-8904	2	_
43-6	8905-8906	×	_
43-7	8907-8922	250-millisecond	_
43-8	8923-8931	segments	_
43-9	8932-8934	to	_
43-10	8935-8943	increase	_
43-11	8944-8949	trial	_
43-12	8950-8957	numbers	_
43-13	8958-8959	(	_
43-14	8960-8963	see	_
43-15	8964-8975	Michalareas	_
43-16	8976-8978	et	_
43-17	8979-8981	al	_
43-18	8982-8983	)	_
43-19	8984-8985	.	_

44-1	8986-8989	The	_
44-2	8990-8996	middle	_
44-3	8997-9006	occipital	_
44-4	9007-9012	gyrus	_
44-5	9013-9016	and	_
44-6	9017-9023	cuneus	_
44-7	9024-9028	ROIs	_
44-8	9029-9033	were	_
44-9	9034-9037	not	_
44-10	9038-9042	used	_
44-11	9043-9045	in	_
44-12	9046-9049	the	_
44-13	9050-9052	GC	_
44-14	9053-9061	analyses	_
44-15	9062-9064	to	_
44-16	9065-9073	minimize	_
44-17	9074-9081	overlap	_
44-18	9082-9089	between	_
44-19	9090-9097	primary	_
44-20	9098-9104	visual	_
44-21	9105-9106	,	_
44-22	9107-9113	dorsal	_
44-23	9114-9115	,	_
44-24	9116-9119	and	_
44-25	9120-9127	ventral	_
44-26	9128-9134	stream	_
44-27	9135-9147	connectivity	_
44-28	9148-9157	estimates	_
44-29	9158-9159	.	_

45-1	9160-9177	Granger-causality	_
45-2	9178-9182	data	_
45-3	9183-9187	from	_
45-4	9188-9192	each	_
45-5	9193-9197	pair	_
45-6	9198-9202	were	_
45-7	9203-9211	averaged	_
45-8	9212-9216	over	_
45-9	9217-9227	hemisphere	_
45-10	9228-9230	to	_
45-11	9231-9237	create	_
45-12	9238-9239	4	_
45-13	9240-9244	main	_
45-14	9245-9248	ROI	_
45-15	9249-9254	pairs	_
45-16	9255-9258	for	_
45-17	9259-9270	statistical	_
45-18	9271-9278	testing	_
45-19	9279-9280	.	_

46-1	9281-9283	To	_
46-2	9284-9293	determine	_
46-3	9294-9297	the	_
46-4	9298-9309	alterations	_
46-5	9310-9312	in	_
46-6	9313-9324	feedforward	_
46-7	9325-9326	(	_
46-8	9327-9329	FF	_
46-9	9330-9331	)	_
46-10	9332-9334	vs	_
46-11	9335-9343	feedback	_
46-12	9344-9345	(	_
46-13	9346-9348	FB	_
46-14	9349-9350	)	_
46-15	9351-9353	GC	_
46-16	9354-9362	activity	_
46-17	9363-9364	,	_
46-18	9365-9367	we	_
46-19	9368-9372	also	_
46-20	9373-9381	computed	_
46-21	9382-9385	the	_
46-22	9386-9394	directed	_
46-23	9395-9404	asymmetry	_
46-24	9405-9410	index	_
46-25	9411-9412	(	_
46-26	9413-9416	DAI	_
46-27	9417-9418	;	_
46-28	9419-9422	see	_
46-29	9423-9434	Michalareas	_
46-30	9435-9437	et	_
46-31	9438-9440	al	_
46-32	9441-9442	,	_
46-33	9443-9449	Bastos	_
46-34	9450-9452	et	_
46-35	9453-9455	al	_
46-36	9456-9457	,	_
46-37	9458-9461	and	_
46-38	9462-9470	eMethods	_
46-39	9471-9473	in	_
46-40	9474-9477	the	_
46-41	9478-9488	Supplement	_
46-42	9489-9490	)	_
46-43	9491-9492	.	_

47-1	9493-9504	Statistical	_
47-2	9505-9513	Analysis	_
47-3	9514-9519	Group	_
47-4	9520-9531	differences	_
47-5	9532-9534	in	_
47-6	9535-9540	trial	_
47-7	9541-9548	numbers	_
47-8	9549-9550	,	_
47-9	9551-9557	γ-band	_
47-10	9558-9562	peak	_
47-11	9563-9572	frequency	_
47-12	9573-9574	,	_
47-13	9575-9585	behavioral	_
47-14	9586-9597	performance	_
47-15	9598-9599	,	_
47-16	9600-9611	demographic	_
47-17	9612-9613	,	_
47-18	9614-9617	and	_
47-19	9618-9626	clinical	_
47-20	9627-9631	data	_
47-21	9632-9636	were	_
47-22	9637-9645	assessed	_
47-23	9646-9650	with	_
47-24	9651-9656	1-way	_
47-25	9657-9662	Welch	_
47-26	9663-9671	analysis	_
47-27	9672-9674	of	_
47-28	9675-9683	variance	_
47-29	9684-9685	(	_
47-30	9686-9691	ANOVA	_
47-31	9692-9693	)	_
47-32	9694-9695	;	_
47-33	9696-9703	2-sided	_
47-34	9704-9705	α	_
47-35	9706-9711	level	_
47-36	9712-9714	of	_
47-37	9715-9718	.05	_
47-38	9719-9720	.	_

48-1	9721-9726	Brief	_
48-2	9727-9737	Assessment	_
48-3	9738-9740	of	_
48-4	9741-9750	Cognition	_
48-5	9751-9753	in	_
48-6	9754-9767	Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
48-7	9768-9772	data	_
48-8	9773-9777	were	_
48-9	9778-9783	first	_
48-10	9784-9796	z-normalized	_
48-11	9797-9799	to	_
48-12	9800-9803	the	_
48-13	9804-9806	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
48-14	9807-9811	data	_
48-15	9812-9813	.	_

49-1	9814-9827	Bootstrapping	_
49-2	9828-9829	(	_
49-3	9830-9831	n	_
49-4	9832-9833	=	_
49-5	9834-9838	1000	_
49-6	9839-9840	)	_
49-7	9841-9844	and	_
49-8	9845-9857	Games-Howell	_
49-9	9858-9868	correction	_
49-10	9869-9873	were	_
49-11	9874-9878	used	_
49-12	9879-9881	to	_
49-13	9882-9889	control	_
49-14	9890-9894	type	_
49-15	9895-9896	I	_
49-16	9897-9903	errors	_
49-17	9904-9906	in	_
49-18	9907-9911	post	_
49-19	9912-9915	hoc	_
49-20	9916-9924	pairwise	_
49-21	9925-9930	group	_
49-22	9931-9942	comparisons	_
49-23	9943-9944	.	_

50-1	9945-9956	Statistical	_
50-2	9957-9964	testing	_
50-3	9965-9967	of	_
50-4	9968-9973	group	_
50-5	9974-9985	differences	_
50-6	9986-9988	in	_
50-7	9989-9992	MEG	_
50-8	9993-10008	virtual-channel	_
50-9	10009-10013	data	_
50-10	10014-10022	included	_
50-11	10023-10036	nonparametric	_
50-12	10037-10054	Monte-Carlo–based	_
50-13	10055-10066	permutation	_
50-14	10067-10068	(	_
50-15	10069-10070	n	_
50-16	10071-10072	=	_
50-17	10073-10077	2000	_
50-18	10078-10079	)	_
50-19	10080-10091	independent	_
50-20	10092-10093	F	_
50-21	10094-10098	test	_
50-22	10099-10100	(	_
50-23	10101-10105	main	_
50-24	10106-10111	group	_
50-25	10112-10118	effect	_
50-26	10119-10120	)	_
50-27	10121-10124	and	_
50-28	10125-10129	post	_
50-29	10130-10133	hoc	_
50-30	10134-10135	t	_
50-31	10136-10140	test	_
50-32	10141-10151	statistics	_
50-33	10152-10155	for	_
50-34	10156-10160	ERFs	_
50-35	10161-10162	(	_
50-36	10163-10168	0-750	_
50-37	10169-10181	milliseconds	_
50-38	10182-10183	)	_
50-39	10184-10185	;	_
50-40	10186-10190	TFRs	_
50-41	10191-10194	and	_
50-42	10195-10199	ITPC	_
50-43	10200-10205	power	_
50-44	10206-10207	(	_
50-45	10208-10212	1-90	_
50-46	10213-10215	Hz	_
50-47	10216-10217	,	_
50-48	10218-10223	0-750	_
50-49	10224-10236	milliseconds	_
50-50	10237-10240	for	_
50-51	10241-10244	TFR	_
50-52	10245-10250	power	_
50-53	10251-10252	,	_
50-54	10253-10258	0-350	_
50-55	10259-10271	milliseconds	_
50-56	10272-10275	for	_
50-57	10276-10280	ITPC	_
50-58	10281-10282	,	_
50-59	10283-10286	and	_
50-60	10287-10289	dB	_
50-61	10290-10296	change	_
50-62	10297-10301	from	_
50-63	10302-10303	a	_
50-64	10304-10319	500-millisecond	_
50-65	10320-10328	baseline	_
50-66	10329-10330	)	_
50-67	10331-10332	;	_
50-68	10333-10341	baseline	_
50-69	10342-10345	FFT	_
50-70	10346-10353	spectra	_
50-71	10354-10355	(	_
50-72	10356-10360	1-90	_
50-73	10361-10363	Hz	_
50-74	10364-10365	)	_
50-75	10366-10367	;	_
50-76	10368-10371	and	_
50-77	10372-10374	GC	_
50-78	10375-10379	data	_
50-79	10380-10381	.	_

51-1	10382-10386	Type	_
51-2	10387-10388	I	_
51-3	10389-10395	errors	_
51-4	10396-10400	were	_
51-5	10401-10411	controlled	_
51-6	10412-10414	by	_
51-7	10415-10422	cluster	_
51-8	10423-10433	statistics	_
51-9	10434-10440	across	_
51-10	10441-10445	time	_
51-11	10446-10452	and/or	_
51-12	10453-10462	frequency	_
51-13	10463-10464	(	_
51-14	10465-10473	eMethods	_
51-15	10474-10476	in	_
51-16	10477-10480	the	_
51-17	10481-10491	Supplement	_
51-18	10492-10493	)	_
51-19	10494-10495	.	_

52-1	10496-10503	Finally	_
52-2	10504-10505	,	_
52-3	10506-10512	binary	_
52-4	10513-10521	logistic	_
52-5	10522-10532	regression	_
52-6	10533-10536	and	_
52-7	10537-10545	receiver	_
52-8	10546-10555	operating	_
52-9	10556-10570	characteristic	_
52-10	10571-10576	curve	_
52-11	10577-10578	(	_
52-12	10579-10582	ROC	_
52-13	10583-10584	)	_
52-14	10585-10593	analyses	_
52-15	10594-10598	were	_
52-16	10599-10603	used	_
52-17	10604-10606	to	_
52-18	10607-10614	examine	_
52-19	10615-10618	the	_
52-20	10619-10630	association	_
52-21	10631-10638	between	_
52-22	10639-10642	MEG	_
52-23	10643-10653	parameters	_
52-24	10654-10657	and	_
52-25	10658-10666	clinical	_
52-26	10667-10675	outcomes	_
52-27	10676-10678	in	_
52-28	10679-10684	CHR-P	_
52-29	10685-10697	participants	_
52-30	10698-10699	(	_
52-31	10700-10708	eMethods	_
52-32	10709-10711	in	_
52-33	10712-10715	the	_
52-34	10716-10726	Supplement	_
52-35	10727-10728	)	_
52-36	10729-10730	.	_

